. 2013 May;41(5):975–986. doi: 10.1124/dmd.112.050724

TABLE 3.

Noncompartmental analysis of serum bufotenine PK in wild-type and Tg-CYP2D6 mice coadministered with harmaline and 5-MeO-DMT

Harmaline and 5-MeO-DMT were administered i.p. at 0 and 15 minutes, respectively.

Mice	Parameters	5-MeO-DMT 2 mg/kg			5-MeO-DMT 10 mg/kg
Mice	Parameters	Harmaline 0 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg	Harmaline 0 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg
Wild-type	C_max (µM)	0.051 ± 0.009	0.132 ± 0.009^*	0.075 ± 0.015^*^&	0.114 ± 0.023	0.185 ± 0.014^*	0.131 ± 0.037^*^&
Wild-type	AUC (µM⋅min)^a	2.69 ± 1.21	16.3 ± 1.4^*	5.16 ± 0.76^*^&	5.66 ± 0.88	12.9 ± 1.2^*	2.72 ± 0.34^*^&
Tg-CYP2D6	C_max (µM)	0.053 ± 0.013	0.137 ± 0.014^*	0.090 ± 0.010^*^&	0.151 ± 0.085	0.300 ± 0.030^*^#	0.170 ± 0.066^*^&
Tg-CYP2D6	AUC (µM⋅min)^a	1.82 ± 0.74	18.0 ± 1.5^*	6.86 ± 1.33^*^&	7.30 ± 4.21	18.2 ± 1.9^*^#	3.59 ± 0.94^*^&

^{^a}

AUC_15→105min for the treatments of 5 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, AUC_15→45min for the treatments of 15 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, and AUC_{15 min→∞} for all other treatments.

P < 0.05 compared with corresponding values for the same genotype mice treated with the same dose of 5-MeO-DMT alone; ^&P < 0.05 compared with corresponding values for the same genotype mice treated with the same dose of 5-MeO-DMT plus 5 mg/kg harmaline; ^#P < 0.05 compared with wild-type mice under the same treatment.